Prudential Financial
CTMX icon

Prudential Financial’s CytomX Therapeutics CTMX Stock Holding History

Prudential Financial’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
+27,950
New +$107K ﹤0.01% 2334
2025
Q4 		– Sell
-23,300
Closed -$74.3K – 2264
2025
Q3 		$74.3K Sell
23,300
-2,400
-9% -$5.41K ﹤0.01% 2303
2025
Q2 		$58.3K Sell
25,700
-55,800
-68% -$89.9K ﹤0.01% 2333
2025
Q1 		$51.8K Buy
81,500
+17,200
+27% +$13.3K ﹤0.01% 2196
2024
Q4 		$66.2K Buy
64,300
+27,800
+76% +$29.9K ﹤0.01% 2188
2024
Q3 		$43.1K Hold
36,500
– – ﹤0.01% 2662
2024
Q2 		$44.5K Buy
36,500
+4,600
+14% +$9.16K ﹤0.01% 2625
2024
Q1 		$69.5K Buy
31,900
+15,600
+96% +$28.8K ﹤0.01% 2564
2023
Q4 		$25.3K Hold
16,300
– – ﹤0.01% 2604
2023
Q3 		$21K Sell
16,300
-8,400
-34% -$13.2K ﹤0.01% 2568
2023
Q2 		$42.5K Sell
24,700
-2,400
-9% -$3.98K ﹤0.01% 2551
2023
Q1 		$40.9K Hold
27,100
– – ﹤0.01% 2517
2022
Q4 		$43.4K Hold
27,100
– – ﹤0.01% 2507
2022
Q3 		$39K Buy
27,100
+7,400
+38% +$11.4K ﹤0.01% 2579
2022
Q2 		$36K Buy
+19,700
New +$37.7K ﹤0.01% 2590
2021
Q1 		– Sell
-83,040
Closed -$544K – 2496
2020
Q4 		$544K Sell
83,040
-72,900
-47% -$521K ﹤0.01% 2030
2020
Q3 		$1.04M Sell
155,940
-90,229
-37% -$669K ﹤0.01% 1626
2020
Q2 		$2.05M Sell
246,169
-96,842
-28% -$899K ﹤0.01% 1325
2020
Q1 		$2.63M Sell
343,011
-118,135
-26% -$824K 0.01% 1231
2019
Q4 		$3.83M Buy
461,146
+344
+0.1% +$2.32K 0.01% 1253
2019
Q3 		$3.4M Buy
460,802
+225,530
+96% +$2.22M 0.01% 1301
2019
Q2 		$2.64M Buy
235,272
+146,647
+165% +$1.54M ﹤0.01% 1463
2019
Q1 		$953K Buy
+88,625
New +$1.31M ﹤0.01% 1894
2018
Q1 		– Sell
-29,210
Closed -$617K – 2354
2017
Q4 		$617K Buy
+29,210
New +$606K ﹤0.01% 1962
2017
Q2 		– Sell
-28,070
Closed -$485K – 2353
2017
Q1 		$485K Buy
+28,070
New +$369K ﹤0.01% 2037

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Prudential Financial's CTMX Position: Q2 2026 in Review

Prudential Financial opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 27,950 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #2334 among its holdings. This is a return to the name: Prudential Financial previously reported a position in CTMX as recently as Q3 2025.

Prudential Financial first reported a position in CTMX in Q1 2017 and has held it in 25 quarters since. The position peaked at $3.83M in Q4 2019. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Prudential Financial held 27,950 shares of CytomX Therapeutics worth $105K as of Q2 2026.
  • CytomX Therapeutics was a new Prudential Financial position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2334 holding.
  • Prudential Financial first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 25 quarters since.
  • Prudential Financial's CytomX Therapeutics position peaked at $3.83M in Q4 2019.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.